Joaquı́n Arribas

Institució Catalana de Recerca i Estudis Avançats

Also affiliated with Instituto de Salud Carlos III, Vall d'Hebron Institut de Recerca, Hospital Del Mar, Centro de Investigación Biomédica en Red de Cáncer, Vall d'Hebron Institute of Oncology

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts”.

Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3324

N/A

0DataRank · unranked

41 citations

Marta Palafox, Laia Monserrat, Fara Brasó‐Maristany, Andreu Òdena, Mònica Sánchez-Guixé +26 more

Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns

Genome Medicine(2020)10.1186/s13073-020-00774-x

N/A

0DataRank · unranked

23 citations

Miquel Duran‐Frigola, Albert Gris‐Oliver, Marta Palafox, Maurizio Scaltriti, Pedram Razavi +6 more

HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway

Nature Communications(2021)10.1038/s41467-021-27093-y

N/A

0DataRank · unranked

88 citations

Emanuela Ferraro, Anton Safonov, Cristina Bernadó Morales, Enrique J. Arenas, Qing Li +10 more

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Research Square(2021)10.21203/rs.3.rs-236645/v1

N/A

0DataRank · unranked

12 citations

Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel González-Pérez, Mafalda Oliveira +33 more

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Nature Communications(2022)10.1038/s41467-022-32828-6

N/A

0DataRank · unranked

121 citations

Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel González-Pérez, Mafalda Oliveira +33 more

Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification

Cancer Research(2022)10.1158/0008-5472.can-21-2409

N/A

0DataRank · unranked

98 citations

Andrea Herencia-Ropero, Alba Llop‐Guevara, Flaminia Pedretti, Alejandro Moles‐Fernández, Cristina Viaplana +34 more

The efficacy of chemotherapy is limited by intratumoural senescent cells that persist through the upregulation of PD-L2

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.11.04.501681

N/A

0DataRank · unranked

7 citations

José A López-Domínguez, Marta Lalinde-Gutiérrez, Neus Prats, Inés Marín, Kathleen Meyer +14 more

Data from Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification

(2023)10.1158/0008-5472.c.6513876.v1

N/A

0DataRank · unranked

0 citations

Andrea Herencia-Ropero, Alba Llop‐Guevara, Flaminia Pedretti, Alejandro Moles‐Fernández, Cristina Viaplana +34 more

The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2

Nature Cancer(2024)10.1038/s43018-023-00712-x

N/A

0DataRank · unranked

99 citations

José A López-Domínguez, Marta Lalinde-Gutiérrez, Neus Prats, Inés Marín, Olga Boix +18 more

Estrogen receptor signaling drives immune evasion and immunotherapy resistance in HR+ breast cancer

Journal of Clinical Investigation(2025)10.1172/jci193153

N/A

0DataRank · unranked

3 citations

Gabriel Serra-Mir, Sandra Blasco-Benito, Héléna Brunel, Pau Torren-Duran, Iván Pérez-Núñez +18 more